PURPOSE: The aim of this study was to determine the usefulness of MRI-assisted positron emission tomography (PET) parameters provided by simultaneous (18)F-fluorocholine (FCH) PET/MRI for characterization of primary prostate cancer. METHODS: Thirty patients with localized prostate cancer (mean age 69.4 ± 6.7 years) confirmed by biopsy were prospectively enrolled for simultaneous PET/MRI imaging. The patients underwent (18)F-FCH PET/MRI 1 week before undergoing total prostatectomy. Multiple parameters of diffusion-weighted MRI [minimum and mean apparent diffusion coefficient (ADCmin and ADCmean)], metabolic PET [maximum and mean standardized uptake value (SUVmax and SUVmean)], and metabolic volumetric PET [metabolic tumor volume (MTV) and uptake volume product (UVP)] were compared with laboratory, pathologic, and immunohistochemical (IHC) features of the prostate cancer specimen. PET parameters were divided into two categories as follows: volume of interest (VOI) of prostate by SUV cutoff 2.5 (SUVmax, SUVmean, MTVSUV, and UVPSUV) and MRI-assisted VOI of prostate cancer (SUVmaxMRI, SUVmeanMRI, MTVMRI, and UVPMRI). RESULTS: The rates of prostate cancer-positive cases identified by MRI alone, (18)F-FCH PET alone, and (18)F-FCH PET/MRI were 83.3, 80.0, and 93.3%, respectively. Among the multiple PET/MRI parameters, MTVMRI showed fair correlation with serum prostate-specific antigen (PSA; r = 0.442, p = 0.014) and highest correlation with tumor volume (r = 0.953, p < 0.001). UVPMRI showed highest correlation with serum PSA (r = 0.531, p = 0.003), good correlation with tumor volume (r = 0.908, p < 0.001), and it was significantly associated with Gleason score (p = 0.041). High MTVMRI and UVPMRI values were significant for perineural invasion, lymphatic invasion, extracapsular extension, seminal vesicle invasion, and positive B-cell lymphoma 2 (Bcl-2) expression (all p < 0.05). CONCLUSION: Simultaneous (18)F-FCH PET/MRI demonstrated a better diagnostic value for localized prostate cancer detection than each individual modality. MRI-assisted metabolic volumetric PET parameters (MTVMRI and UVPMRI) provided more accurate characterization of prostate cancer than conventional PET and MRI parameters.
PURPOSE: The aim of this study was to determine the usefulness of MRI-assisted positron emission tomography (PET) parameters provided by simultaneous (18)F-fluorocholine (FCH) PET/MRI for characterization of primary prostate cancer. METHODS: Thirty patients with localized prostate cancer (mean age 69.4 ± 6.7 years) confirmed by biopsy were prospectively enrolled for simultaneous PET/MRI imaging. The patients underwent (18)F-FCH PET/MRI 1 week before undergoing total prostatectomy. Multiple parameters of diffusion-weighted MRI [minimum and mean apparent diffusion coefficient (ADCmin and ADCmean)], metabolic PET [maximum and mean standardized uptake value (SUVmax and SUVmean)], and metabolic volumetric PET [metabolic tumor volume (MTV) and uptake volume product (UVP)] were compared with laboratory, pathologic, and immunohistochemical (IHC) features of the prostate cancer specimen. PET parameters were divided into two categories as follows: volume of interest (VOI) of prostate by SUV cutoff 2.5 (SUVmax, SUVmean, MTVSUV, and UVPSUV) and MRI-assisted VOI of prostate cancer (SUVmaxMRI, SUVmeanMRI, MTVMRI, and UVPMRI). RESULTS: The rates of prostate cancer-positive cases identified by MRI alone, (18)F-FCH PET alone, and (18)F-FCH PET/MRI were 83.3, 80.0, and 93.3%, respectively. Among the multiple PET/MRI parameters, MTVMRI showed fair correlation with serum prostate-specific antigen (PSA; r = 0.442, p = 0.014) and highest correlation with tumor volume (r = 0.953, p < 0.001). UVPMRI showed highest correlation with serum PSA (r = 0.531, p = 0.003), good correlation with tumor volume (r = 0.908, p < 0.001), and it was significantly associated with Gleason score (p = 0.041). High MTVMRI and UVPMRI values were significant for perineural invasion, lymphatic invasion, extracapsular extension, seminal vesicle invasion, and positive B-cell lymphoma 2 (Bcl-2) expression (all p < 0.05). CONCLUSION: Simultaneous (18)F-FCH PET/MRI demonstrated a better diagnostic value for localized prostate cancer detection than each individual modality. MRI-assisted metabolic volumetric PET parameters (MTVMRI and UVPMRI) provided more accurate characterization of prostate cancer than conventional PET and MRI parameters.
Authors: Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-02-07 Impact factor: 9.236
Authors: S M Schwarzenböck; J Kurth; Ch Gocke; T Kuhnt; G Hildebrandt; B J Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-11 Impact factor: 9.236
Authors: Thomas A Hope; Zahi A Fayad; Kathryn J Fowler; Dawn Holley; Andrei Iagaru; Alan B McMillan; Patrick Veit-Haiback; Robert J Witte; Greg Zaharchuk; Ciprian Catana Journal: J Nucl Med Date: 2019-05-23 Impact factor: 10.057
Authors: Joon Young Choi; Jaewon Yang; Susan M Noworolski; Spencer Behr; Albert J Chang; Jeffry P Simko; Hao G Nguyen; Peter R Carroll; John Kurhanewicz; Youngho Seo Journal: Radiology Date: 2016-08-11 Impact factor: 11.105
Authors: Min Young Yoo; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; E Edmund Kim; Keon Wook Kang Journal: Nucl Med Mol Imaging Date: 2015-08-29
Authors: Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook Journal: Diagnostics (Basel) Date: 2015-07-21
Authors: Jurgen J Futterer; Cristian Surcel; Roderick van den Bergh; Hendrik Borgmann; Alberto Briganti; Giorgio Gandaglia; Alexander Kretschmer; Piet Ost; Prasanna Sooriakumaran; Derya Tilki; Massimo Valerio; Guillaume Ploussard; Pieter J L De Visschere; Igor Tsaur Journal: World J Urol Date: 2018-08-01 Impact factor: 4.226
Authors: Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli Journal: Front Oncol Date: 2016-03-31 Impact factor: 6.244